Hormonal therapy for menopause and ovarian cancer in a collaborative re- analysis of European studies

Eva Negri, Anastasia Tzonou, Valerie Beral, Pagona Lagiou, Dimitrios Trichopoulos, Fabio Parazzini, Silvia Franceschi, Margareth Booth, Carlo La Vecchia

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

The relationship between hormonal therapy for menopause (hormone replacement therapy, HRT) and the risk of epithelial ovarian cancer was evaluated in a collaborative re-analysis of 4 European case-control studies, 2 conducted in Greece and 1 each in Italy and the United Kingdom, including a total of 1,470 ovarian cancer cases and 3,271 hospital controls. Odds ratios (ORs) for HRT use were derived after allowance for study centre, age, socio- economic level, parity, menopausal status, type of menopause, age at menopause and oral contraceptive use. Overall, 109 (8.0%) ovarian cancer cases and 146 (4.7%) controls had ever used HRT, corresponding to an adjusted OR of 1.71 (95% confidence interval 1.30-2.25). The point estimates of the OR were 1.77 in the first Greek study, 1.40 in the second Greek study, 1.66 in the Italian study and 1.68 in the British study. Adjustment for possible confounders, including menopausal status, type of menopause, age at menopause and oral contraceptive use, slightly increased the OR. Limiting the analysis to women with information on relevant aspects of HRT use revealed a weak positive association with duration and some evidence that the excess relative risk for ovarian cancer declined with time since last use. These findings are compatible with a promoting effect of HRT in ovarian carcinogenesis. It is also possible, however, that the positive association reflects chance or selective administration of HRT to high-risk individuals, since until recently in Europe HRT was prescribed mainly for alleviation of peri- menopausal symptoms.

Original languageEnglish
Pages (from-to)848-851
Number of pages4
JournalInternational Journal of Cancer
Volume80
Issue number6
DOIs
Publication statusPublished - Mar 15 1999

Fingerprint

Hormone Replacement Therapy
Menopause
Ovarian Neoplasms
Odds Ratio
Oral Contraceptives
Therapeutics
Greece
Parity
Italy
Case-Control Studies
Carcinogenesis
Economics
Confidence Intervals

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hormonal therapy for menopause and ovarian cancer in a collaborative re- analysis of European studies. / Negri, Eva; Tzonou, Anastasia; Beral, Valerie; Lagiou, Pagona; Trichopoulos, Dimitrios; Parazzini, Fabio; Franceschi, Silvia; Booth, Margareth; La Vecchia, Carlo.

In: International Journal of Cancer, Vol. 80, No. 6, 15.03.1999, p. 848-851.

Research output: Contribution to journalArticle

Negri, Eva ; Tzonou, Anastasia ; Beral, Valerie ; Lagiou, Pagona ; Trichopoulos, Dimitrios ; Parazzini, Fabio ; Franceschi, Silvia ; Booth, Margareth ; La Vecchia, Carlo. / Hormonal therapy for menopause and ovarian cancer in a collaborative re- analysis of European studies. In: International Journal of Cancer. 1999 ; Vol. 80, No. 6. pp. 848-851.
@article{e87fe008ca3c40068cfde6a9b9b0d8ec,
title = "Hormonal therapy for menopause and ovarian cancer in a collaborative re- analysis of European studies",
abstract = "The relationship between hormonal therapy for menopause (hormone replacement therapy, HRT) and the risk of epithelial ovarian cancer was evaluated in a collaborative re-analysis of 4 European case-control studies, 2 conducted in Greece and 1 each in Italy and the United Kingdom, including a total of 1,470 ovarian cancer cases and 3,271 hospital controls. Odds ratios (ORs) for HRT use were derived after allowance for study centre, age, socio- economic level, parity, menopausal status, type of menopause, age at menopause and oral contraceptive use. Overall, 109 (8.0{\%}) ovarian cancer cases and 146 (4.7{\%}) controls had ever used HRT, corresponding to an adjusted OR of 1.71 (95{\%} confidence interval 1.30-2.25). The point estimates of the OR were 1.77 in the first Greek study, 1.40 in the second Greek study, 1.66 in the Italian study and 1.68 in the British study. Adjustment for possible confounders, including menopausal status, type of menopause, age at menopause and oral contraceptive use, slightly increased the OR. Limiting the analysis to women with information on relevant aspects of HRT use revealed a weak positive association with duration and some evidence that the excess relative risk for ovarian cancer declined with time since last use. These findings are compatible with a promoting effect of HRT in ovarian carcinogenesis. It is also possible, however, that the positive association reflects chance or selective administration of HRT to high-risk individuals, since until recently in Europe HRT was prescribed mainly for alleviation of peri- menopausal symptoms.",
author = "Eva Negri and Anastasia Tzonou and Valerie Beral and Pagona Lagiou and Dimitrios Trichopoulos and Fabio Parazzini and Silvia Franceschi and Margareth Booth and {La Vecchia}, Carlo",
year = "1999",
month = "3",
day = "15",
doi = "10.1002/(SICI)1097-0215(19990315)80:6<848::AID-IJC8>3.0.CO;2-E",
language = "English",
volume = "80",
pages = "848--851",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Hormonal therapy for menopause and ovarian cancer in a collaborative re- analysis of European studies

AU - Negri, Eva

AU - Tzonou, Anastasia

AU - Beral, Valerie

AU - Lagiou, Pagona

AU - Trichopoulos, Dimitrios

AU - Parazzini, Fabio

AU - Franceschi, Silvia

AU - Booth, Margareth

AU - La Vecchia, Carlo

PY - 1999/3/15

Y1 - 1999/3/15

N2 - The relationship between hormonal therapy for menopause (hormone replacement therapy, HRT) and the risk of epithelial ovarian cancer was evaluated in a collaborative re-analysis of 4 European case-control studies, 2 conducted in Greece and 1 each in Italy and the United Kingdom, including a total of 1,470 ovarian cancer cases and 3,271 hospital controls. Odds ratios (ORs) for HRT use were derived after allowance for study centre, age, socio- economic level, parity, menopausal status, type of menopause, age at menopause and oral contraceptive use. Overall, 109 (8.0%) ovarian cancer cases and 146 (4.7%) controls had ever used HRT, corresponding to an adjusted OR of 1.71 (95% confidence interval 1.30-2.25). The point estimates of the OR were 1.77 in the first Greek study, 1.40 in the second Greek study, 1.66 in the Italian study and 1.68 in the British study. Adjustment for possible confounders, including menopausal status, type of menopause, age at menopause and oral contraceptive use, slightly increased the OR. Limiting the analysis to women with information on relevant aspects of HRT use revealed a weak positive association with duration and some evidence that the excess relative risk for ovarian cancer declined with time since last use. These findings are compatible with a promoting effect of HRT in ovarian carcinogenesis. It is also possible, however, that the positive association reflects chance or selective administration of HRT to high-risk individuals, since until recently in Europe HRT was prescribed mainly for alleviation of peri- menopausal symptoms.

AB - The relationship between hormonal therapy for menopause (hormone replacement therapy, HRT) and the risk of epithelial ovarian cancer was evaluated in a collaborative re-analysis of 4 European case-control studies, 2 conducted in Greece and 1 each in Italy and the United Kingdom, including a total of 1,470 ovarian cancer cases and 3,271 hospital controls. Odds ratios (ORs) for HRT use were derived after allowance for study centre, age, socio- economic level, parity, menopausal status, type of menopause, age at menopause and oral contraceptive use. Overall, 109 (8.0%) ovarian cancer cases and 146 (4.7%) controls had ever used HRT, corresponding to an adjusted OR of 1.71 (95% confidence interval 1.30-2.25). The point estimates of the OR were 1.77 in the first Greek study, 1.40 in the second Greek study, 1.66 in the Italian study and 1.68 in the British study. Adjustment for possible confounders, including menopausal status, type of menopause, age at menopause and oral contraceptive use, slightly increased the OR. Limiting the analysis to women with information on relevant aspects of HRT use revealed a weak positive association with duration and some evidence that the excess relative risk for ovarian cancer declined with time since last use. These findings are compatible with a promoting effect of HRT in ovarian carcinogenesis. It is also possible, however, that the positive association reflects chance or selective administration of HRT to high-risk individuals, since until recently in Europe HRT was prescribed mainly for alleviation of peri- menopausal symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0033559179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033559179&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19990315)80:6<848::AID-IJC8>3.0.CO;2-E

DO - 10.1002/(SICI)1097-0215(19990315)80:6<848::AID-IJC8>3.0.CO;2-E

M3 - Article

C2 - 10074916

AN - SCOPUS:0033559179

VL - 80

SP - 848

EP - 851

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -